RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 3

Registered title, quoted from ClinicalTrials.gov

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 42 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 42

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Hospital of Guizhou Medical University贵州医科大学附属医院GuiyangHospital page
  2. Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
  3. Study siteAffiliated Hospital of Xuzhou Medical University徐州医科大学附属医院XuzhouHospital page
  4. Study siteBeijing GoBroad Hospital北京高博医院BeijingHospital page
  5. Study siteBeijing Tongren Hospital首都医科大学附属北京同仁医院BeijingHospital page
  6. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  7. Study siteFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page
  8. Study siteFirst Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院ChongqingHospital page
  9. Study siteFirst Affiliated Hospital of Guangxi Medical University广西医科大学第一附属医院NanningHospital page
  10. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  11. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  12. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  13. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  14. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  15. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  16. Study siteFujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page
  17. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
  18. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  19. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  20. Study siteHubei Cancer Hospital湖北省肿瘤医院WuhanHospital page
  21. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  22. Study siteInstitute of Hematology & Blood Diseases Hospital, CAMS & PUMC中国医学科学院血液病医院(血液学研究所)TianjinHospital page
  23. Study siteJiangsu Cancer Hospital江苏省肿瘤医院NanjingHospital page
  24. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
  25. Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
  26. Study siteQilu Hospital of Shandong University山东大学齐鲁医院JinanHospital page
  27. Study siteQuanzhou First Hospital, Fujian Medical University福建医科大学附属泉州第一医院QuanzhouHospital page
  28. Study siteRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page
  29. Study siteSecond Affiliated Hospital of Anhui Medical University安徽医科大学第二附属医院HefeiHospital page
  30. Study siteSecond Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院Xi'anHospital page
  31. Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
  32. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  33. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  34. Study siteShengjing Hospital of China Medical University中国医科大学附属盛京医院ShenyangHospital page
  35. Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
  36. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  37. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  38. Study siteTongji Hospital同济大学附属同济医院ShanghaiHospital page
  39. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  40. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  41. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
  42. Study siteZhujiang Hospital南方医科大学珠江医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07409428, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);

    Exclusion criterion 7

  3. ECOG performance status score between 0 and 2;

    Inclusion criterion 3

  4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);

    Exclusion criterion 4

  5. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07409428, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Sign the ICF and be able to follow the requirements of study protocol;
  • Age ≥18 years;
  • ECOG performance status score between 0 and 2;
  • Histopathologically confirmed diagnosis of DLBCL;
  • The investigator judges that the patient's current condition requires further treatment;
  • Patients should have at least one bi-dimensionally measurable lesion;
  • Expected survival is more than 12 weeks;

Exclusion Criteria:

  • Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
  • Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
  • Organ insufficiency;
  • Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
  • History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
  • Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
  • The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
  • Clinically significant active infection;

Quoted from ClinicalTrials.gov, NCT07409428, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07409428, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07409428